January 2021 in “HAMDAN MEDICAL JOURNAL” This study reports that finasteride can effectively treat androgenic alopecia and may reduce prostate cancer risk by 25% in men with risk factors.
13 citations
,
November 2016 in “The Journal of urology/The journal of urology” In a population-based study, over 72,000 older men were examined, and dutasteride showed no increased risk of heart failure, myocardial infarction, or stroke compared to finasteride, as reported by the researchers.
8 citations
,
May 2016 in “Indian Journal of Pharmacology” This case report describes an atypical postfinasteride syndrome in a patient treated with both dutasteride and finasteride for androgenic alopecia, highlighting its multisystem involvement and irreversible nature.
21 citations
,
October 2015 in “Current Drug Targets” This review discusses the comparative efficacy of dutasteride and finasteride for benign prostatic hyperplasia, reporting that while symptom improvements are similar, dutasteride may reduce prostate surgery risk and acute urinary retention more effectively.
1 citations
,
June 2015 in “Cancer” This study reported a significant association between severe teenage acne and an increased risk of melanoma, potentially linked to androgen levels, though causation cannot be confirmed.
This study suggests that the use of finasteride and dutasteride may be linked to a decreased risk of melanoma in white men aged ≥60 years who have benign or malignant prostate tumors.
28 citations
,
August 2014 in “Cancer Causes & Control” In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.
9 citations
,
September 2010 in “Dermatologic Therapy” This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.
33 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.
14 citations
,
November 2008 in “Expert opinion on drug metabolism & toxicology” This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.
6 citations
,
January 2003 in “PubMed” Finasteride reduces prostate size and symptoms with few side effects.